The global pain management devices market is experiencing rapid growth, with forecasts predicting an increase from USD 7.68 billion in 2024 to USD 19.1 billion by 2034, at a steady Compound Annual Growth Rate (CAGR) of 9.54%. This expansion is driven by the increasing prevalence of both acute and chronic pain, coupled with the rising demand for personalized treatment solutions. The adoption of minimally invasive techniques, along with favorable government policies and a strong healthcare infrastructure, are further accelerating this market’s growth.
The pain management devices market, valued at USD 7.68 billion in 2024, is projected to reach USD 8.41 billion by 2025, ultimately soaring to USD 19.1 billion by 2034. The expected CAGR of 9.54% from 2025 to 2034 reflects a promising future for this market segment.
Key factors driving this growth include the global rise in chronic and acute pain conditions, the shift toward personalized pain management treatments, and ongoing advancements in medical device technologies. Furthermore, innovations in AI, machine learning, and neuromodulation techniques are enhancing the effectiveness of pain management solutions, providing better outcomes for patients.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5742
North America continues to dominate the pain management devices market, accounting for 48% of the revenue share in 2024. This leadership is attributed to robust healthcare infrastructure, strong government support, and a high rate of pain management device adoption. Moreover, the increasing awareness of pain-related disorders and the availability of advanced treatment options in this region further consolidate North America’s position.
Asia-Pacific is expected to register the fastest-growing CAGR during the forecast period. This can be attributed to the region’s expanding healthcare infrastructure, growing awareness of pain management therapies, and an increasing number of healthcare facilities implementing advanced pain management technologies.
Neurostimulation Devices: By product, the neurostimulation segment is the dominant market leader in 2024. Neurostimulation devices use electrical stimulation to alter pain signals in the body and can be used to treat conditions that conventional therapies cannot. These devices include transcutaneous electrical nerve stimulation (TENS) and spinal cord stimulation, offering both invasive and non-invasive options for pain relief.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5742
Radiofrequency Ablation Devices: Another significant product segment, radiofrequency ablation, is expected to witness the fastest growth in the market over the forecast period. This minimally invasive procedure involves using heat to target and treat painful nerves, providing long-term relief from chronic pain.
Neuropathic Pain: The neuropathic pain segment registered the highest market share in 2024, primarily due to the increasing prevalence of conditions such as diabetic neuropathy, post-surgical pain, and peripheral neuropathy.
Cancer Pain: The cancer pain segment is expected to show the fastest growth, driven by the global rise in cancer incidences and the increasing number of patients seeking effective pain management solutions during cancer treatment.
Hospitals & Clinics: Hospitals and clinics remain the dominant end-use segment, contributing the largest revenue share in 2024. The adoption of advanced pain management devices, coupled with favorable reimbursement policies, drives demand in this sector. Additionally, hospitals and clinics are often involved in clinical trials, enabling early access to cutting-edge pain management technologies.
Physiotherapy Centers: The physiotherapy center segment is expected to expand rapidly, driven by increasing demand for physical therapies to manage chronic pain. The availability of skilled professionals and specialized equipment further supports this growth.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
The integration of artificial intelligence (AI) in pain management devices holds immense potential for improving patient outcomes. AI can enhance data collection, monitoring, and feedback, leading to more personalized and effective treatment plans for patients with chronic pain. AI-enabled sensors in wearable devices can continuously track vital signs and pain levels, providing real-time information to healthcare providers for more informed decision-making.
While the market is growing rapidly, the high cost of advanced pain management devices presents a challenge, particularly in low- and middle-income countries. The expense associated with advanced treatments, including surgical procedures and rehabilitation, limits accessibility to high-quality pain management solutions. Governments and organizations need to address these affordability issues to ensure widespread access to these life-improving devices.
The future of the pain management devices market looks bright, with significant advancements in technology and treatment methods. Notable developments include the use of minimally invasive and non-invasive devices, which offer faster recovery times and shorter hospital stays. New neuromodulation devices and digital health tools, such as wearable devices, continue to innovate and offer patients improved outcomes.
Several noteworthy industry announcements have shaped the market’s direction in recent months:
Saluda Medical’s Evoke System: In January 2025, Saluda Medical announced a significant funding boost of $100 million for the commercialization of its Evoke System, a closed-loop neuromodulation platform for managing pain.
Silo Pharma’s SP-26 Implant: In November 2024, Silo Pharma entered a collaboration to develop a subcutaneous insertion device for a ketamine-loaded implant designed to manage chronic pain, specifically for fibromyalgia patients.
NeuroOne’s FDA Submission: In April 2025, NeuroOne Medical Technologies Corporation filed a 510(k) submission with the FDA for its trigeminal nerve ablation device, which utilizes the company’s OneRF Ablation System.
Zynex’s TensWave Device: Zynex received FDA approval for its TensWave device, a portable TENS unit that helps manage chronic and acute pain without medication, offering a drug-free solution for pain relief.
The global pain management devices market is poised for substantial growth in the coming years, with technological advancements, increased awareness, and a growing need for effective pain solutions driving demand. North America continues to lead the market, but Asia-Pacific is emerging as a key growth region. The integration of AI and other cutting-edge technologies into pain management devices offers exciting opportunities to improve treatment outcomes and provide personalized care. As the market continues to evolve, the future looks bright for both patients and healthcare professionals alike.
Source : https://www.towardshealthcare.com/insights/pain-management-devices-market-sizing
The global mechanobiology-centered therapy market is emerging as one of the most promising sectors in the healthcare industry, with substantial… Read More
The global connected drug delivery devices market is undergoing a significant transformation. Valued at 7.44 billion in 2024, it is… Read More
The global viral vector gene therapy market is entering a transformative era, witnessing rapid expansion and growing relevance across healthcare… Read More
Market Overview The global subcutaneous biologics market is on a strong growth trajectory, projected to expand from USD 1.89 billion… Read More
The landscape of Primary Progressive Multiple Sclerosis (PPMS) is on the brink of a transformative decade. With innovative research, strategic… Read More
Market Overview The global needle-free drug delivery devices market is on an impressive growth trajectory. Valued at USD 14.24 billion… Read More